Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Edward Lee Carter: DOACs vs Warfarin for LV Thrombus – Are We Getting Closer to an Answer?
Nov 21, 2026, 11:59

Edward Lee Carter: DOACs vs Warfarin for LV Thrombus – Are We Getting Closer to an Answer?

Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:

“DOACs vs Warfarin for Left Ventricular Thrombus: Are We Getting Closer to an Answer?

A new meta-analysis published November 6 in European Heart Journal Open adds important evidence to a longstanding anticoagulation question.

Elbenawi and colleagues evaluated 35 studies involving 6,437 patients, including 7 randomized trials and 28 observational studies.

The pooled findings are encouraging:

  • LV thrombus resolution: OR 1.17 (95% CI 0.99–1.39) – no statistically significant difference.
  • Ischemic stroke: OR 0.77 (0.65–0.92) – favored DOACs.
  • Major bleeding: OR 0.62 (0.48–0.79) – favored DOACs.
  • Noncerebral systemic embolism: OR 0.79 (0.54–1.15) – no statistically significant difference.

But here’s the important distinction.

When the analysis was restricted to randomized trials, efficacy and safety outcomes were similar between DOACs and warfarin.

Trial sequential analysis also indicated that the available evidence remains inconclusive.

And several questions persist:

  • How much do warfarin time in therapeutic range and concurrent antiplatelet therapy influence these findings?
  • Does thrombus morphology or underlying cardiomyopathy affect anticoagulant selection?
  • Are we consistently obtaining follow-up imaging to document thrombus resolution?

The 2022 AHA scientific statement already recognized DOACs as a reasonable alternative to warfarin for LV thrombus.

My takeaway:

The accumulating evidence supports individualized DOAC use in appropriately selected patients, but pooled observational advantages should not be mistaken for randomized proof of superiority.

For anticoagulation stewardship, the goal extends beyond choosing an agent.

It includes appropriate dosing, managing bleeding and embolic risks, reassessing concomitant antiplatelet therapy, and documenting thrombus resolution.

The evidence is evolving. Our clinical decisions must remain grounded in what it actually demonstrates.”

Edward Lee Carter: DOACs vs Warfarin for LV Thrombus - Are We Getting Closer to an Answer?

More posts featuring Edward Lee Carter on Hemostasis Today.